Form 4: Ligand Pharmaceuticals CEO Acquires Shares Through Employee Stock Purchase Plan

Ligand Pharmaceuticals CEO Todd C. Davis acquired 350 shares of common stock through the company's Employee Stock Purchase Plan on June 28, 2024.

Summary

• On June 28, 2024, Todd C. Davis, CEO of Ligand Pharmaceuticals, acquired 350 shares of Ligand's common stock.
• The shares were purchased through the Ligand Employee Stock Purchase Plan at a price of $60.707 per share.
• Following the transaction, Davis directly owns 120,510 shares of Ligand common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a routine transaction. The CEO's purchase could be seen as slightly positive, but it's a small amount relative to their total holdings.

Positives

• The CEO's participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Industry Context

Insider transactions are routinely monitored and reported to the SEC. Purchases by executives can be seen as a positive signal, but the impact is often small unless the purchase is very large.

Stakeholder Impact

• The transaction may have a slightly positive impact on shareholder sentiment due to the CEO's increased investment in the company.

Key Dates